Paul Tudor Jones’s BioMarin Pharmaceuticals BMRN Stock Holding History

Paul Tudor Jones’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,400	Closed	-$531K	–	3587
2026 Q1	$531K	Sell	9,400 -17,300	-65%	-$1.01M	﹤0.01%	2774
2025 Q4	$1.59M	Sell	26,700 -26,000	-49%	-$1.42M	﹤0.01%	1981
2025 Q3	$2.85M	Buy	52,700 +22,300	+73%	+$1.28M	﹤0.01%	1572
2025 Q2	$1.67M	Buy	30,400 +19,800	+187%	+$1.17M	﹤0.01%	1789
2025 Q1	$749K	Sell	10,600 -10,200	-49%	-$686K	﹤0.01%	2016
2024 Q4	$1.37M	Buy	20,800 +15,700	+308%	+$1.05M	0.01%	1506
2024 Q3	$358K	Buy	+5,100	New	+$426K	﹤0.01%	2208

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Paul Tudor Jones's BMRN Position: Q1 2026 in Review

Paul Tudor Jones sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 105,523 shares — an estimated $6.15M sold.

Paul Tudor Jones first reported a position in BMRN in Q3 2014 and held it in 23 quarters. The position peaked at $6.55M in Q4 2024. 557 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Paul Tudor Jones reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 105,523 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $6.15M.
Paul Tudor Jones first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 23 quarters.
Paul Tudor Jones's BioMarin Pharmaceuticals position peaked at $6.55M in Q4 2024.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.